Company Directory - Research & Development
Myricx Pharma (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across viral and other diseases.
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services.
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four leading-edge neuroscientists and stem cell pioneers at The University of California, San Francisco. We are focused on the discovery and development of cell-based therapies to treat intractable neurological disease.
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases. The Company’s advanced portfolio of therapeutic candidates target life-threatening and life-limiting diseases in the inflammation, infection and respiratory space.
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division.
"NuCana" is derived from "New Cancer Agents” and “Nucleotide Analogs”. It represents our goal of inventing, developing and commercialising truly novel, transformational medicines, as well as the proprietary medicinal chemistry platform upon which they are based. Our medicines are completely new cancer treatments.
By transforming recent scientific breakthroughs in axonal degeneration and neuroimmune regulation into neuroprotective medicines, we aim to offer renewed hope for those affected by serious neurological diseases.
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for a broad range of diseases.
OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
ONK Therapeutics is dedicated to optimizing a next generation of off-the-shelf, dual-targeted NK cell therapies for patients with hematological malignancies and solid tumors.
OXGENE™ finds solutions to seemingly impossible problems. Our unique combination of precision engineering and breakthrough science, together with advanced robotics and bioinformatics, accelerates the rational design, discovery and manufacture of cell and gene therapies.
At Obsidian, we are pioneering engineered cell and gene therapies to deliver transformative outcomes for patients.
ObvioHealth is a Virtual Research Organization (VRO) leading the long overdue digitization of health innovation. We launched in 2017, leveraging technological innovation to tackle the inefficiencies in the trial process. But we knew then and now, that success would come from the fusion of experienced clinical researchers and pioneering health technologists.
At Omega Therapeutics, we are pioneering the discovery of epigenomic targets to develop a new class of therapeutics to fundamentally transform human medicine in the service of patients. Our objective is to become the leading digital and data-driven epigenetic medicines company.
Orchard was founded in 2015 — but our roots run deeper, going back to some of the first research and clinical development involving ex vivo autologous gene therapy. We’re proud that our scientists have played a central role in the evolution of this technology from a bold vision to a potentially life-transforming reality.
Orum Therapeutics is combining the precision of antibodies with the power of targeted protein degraders to bring new medicines to patients with unmet medical needs. Orum (오름) means ‘ascent’ in Korean, climbing or moving upwards. Our vision is a world where no patient suffers from diseases caused by undruggable targets.
Oxford Drug Design is based in Oxford, UK. Founded in 2001 as a spin-out company from the Oxford University Chemistry Department by its Chairman, Professor Graham Richards...
